Spruce Biosciences, Inc
Spruce Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for neurological and endocrine disorders with significant unmet medical need. Its pipeline has included product candidates such as tildacerfont, TA-ERT, and SPR202, with development and potential commercialization centered primarily in the United States and selected international markets through partnerships.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaA small-molecule product candidate developed for diseases with high unmet need, including congenital adrenal hyperplasia.
An enzyme replacement therapy candidate being developed for a rare disease indication.
Earlier-stage internal programs and future product candidates under development.
License-based revenue and potential milestones or royalties from partnered development programs.
Asiakkaat
Spruce’s direct customers are not commercial patients or hospitals today; instead, its economic counterparties are licensing partners, regulators, and future healthcare providers that would use approved therapies. The company’s current revenue model depends on collaboration and licensing arrangements, while its future commercial customers would be physicians, specialty pharmacies, and health systems treating rare or specialized diseases. In Japan, Kaken Pharmaceutical is the disclosed partner for tildacerfont in CAH.
Partners such as Kaken that obtain rights to develop and commercialize a candidate in a specific territory.
Endocrinologists, neurologists, and other specialists who would prescribe approved therapies for rare diseases.
Private and government payers that influence adoption through coverage, formulary status, and reimbursement.
Distribution and care-delivery channels that would dispense or administer approved products.
Strategia
Spruce’s strategy is to advance a portfolio of therapies for diseases with significant unmet need, with emphasis on clinical development, regulatory progress, and partnering where appropriate. The company also seeks to build or access commercialization capabilities for any approved product, while using collaborations to extend reach in selected territories. Its near-term direction is shaped by which programs advance and whether external partners can support development or commercialization.
Clinical and regulatory progress is the main driver of future value creation.
Partnerships can provide development support and market access without building a full global sales force.
If a candidate is approved, the company needs sales, distribution, and reimbursement capabilities.
Maantiede
Spruce is headquartered in the United States and conducts its development and corporate activities primarily from there. Its disclosed commercial geography is limited, but the Kaken license gives a partner exclusive rights to develop and commercialize tildacerfont for CAH in Japan, creating a non-U.S. revenue and regulatory exposure. The company also references regulatory pathways in the EU and other foreign jurisdictions as potential markets for future product candidates.
Riskit
Spruce is a development-stage biopharmaceutical company, so its value depends on clinical success, regulatory approval, and eventual market adoption of one or more candidates. It also faces financing, commercialization, and listing risks typical of small-cap biotech companies, including the need to fund operations before product revenue exists and the possibility that approved products may never reach meaningful sales.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Pipeline value depends on demonstrating safety and efficacy in trials.
Kohdistuu - Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
The company has disclosed insufficient working capital for planned operations.
Kohdistuu: Corporate funding and operations
- Regulatory approval delays or denialsVaikutus: KorkeaTodennäköisyys: Korkea
Products cannot be commercialized without FDA and other approvals.
Kohdistuu - Commercialization and launch execution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has no established sales and marketing organization.
Kohdistuu: Future approved products
- Nasdaq listing compliance riskVaikutus: KeskitasoTodennäköisyys: Korkea
Delisting could reduce liquidity and investor access to the stock.
Kohdistuu: Common stock trading
Kirjanpito
Harkinnanvaraiset erätRevenue from the Kaken License Agreement is recognized only when accounting criteria are met, affecting timing and volatility.
Vaikutus: Milestones and royalties may be lumpy and non-recurring
Clinical, preclinical, manufacturing, and internal personnel costs are expensed as incurred, shaping reported losses.
Vaikutus: Quarterly results can shift with trial activity and development timing
Changes in fair value can create non-operating gains or losses unrelated to core operations.
Vaikutus: Can materially affect net income or loss
Loan obligations and repayments affect cash flow and balance-sheet leverage presentation.
Vaikutus: Important for liquidity analysis
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Forte Biosciences, Inc.
Pharmaceutical Preparations
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
Jade Biosciences, Inc.
JBIO · Pharmaceutical Preparations
Takeda Pharmaceutical Company Limited
TAK · Pharmaceutical Preparations
Takeda Pharmaceutical is a Japan-headquartered biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines.
Päivitetty: 24.9.2026